LncRNA evf-2 and Podocyte Injury in Diabetic Nephropathy
Author Information
Author(s): Zhang Chaojie, Zhao Hui, Yan Yufan, Li Yanfei, Lei Min, Liu Yong, Yang Longhua, Zhao Huijian, Zhou Sijie, Pan Shaokang, Liu Zhangsuo, Guo Jia
Primary Institution: Nephrology Research Center, the First Affiliated Hospital of Zhengzhou University
Hypothesis
LncRNA evf-2 exacerbates podocyte injury in diabetic nephropathy by inducing cell cycle re-entry and inflammation through distinct mechanisms triggered by hnRNPU.
Conclusion
The study reveals that lncRNA evf-2 plays a crucial role in podocyte injury in diabetic nephropathy, suggesting it as a potential target for gene therapy.
Supporting Evidence
- lncRNA evf-2 is upregulated in podocytes of diabetic nephropathy patients.
- Knockdown of lncRNA evf-2 alleviated podocyte injury in diabetic mice.
- RNA sequencing revealed upregulation of mRNAs in cell cycle and inflammation pathways.
- Chromatin isolation by RNA purification-mass spectrometry analysis highlighted hnRNPU as the main binding partner of evf-2.
Takeaway
This study found that a molecule called lncRNA evf-2 can make kidney cells called podocytes hurt more when someone has diabetes, which could help doctors find new ways to treat kidney problems.
Methodology
The study used RNA sequencing, immunohistochemistry, and various mouse models to investigate the role of lncRNA evf-2 in podocyte injury.
Limitations
The study primarily focuses on the role of lncRNA evf-2 without exploring other potential factors involved in podocyte injury.
Participant Demographics
The study included renal biopsy samples from 3 diabetic nephropathy patients, 3 diabetes mellitus patients, and 3 normal controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website